分组1 - BioHarvest Sciences Inc. reported a quarterly loss of $0.14 per share, which is an improvement from a loss of $0.16 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $9.07 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.74%, but showing an increase from $6.54 million year-over-year [2] - The stock has increased approximately 27.8% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] 分组2 - The earnings outlook for BioHarvest Sciences Inc. is uncertain, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.59 for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The estimate revisions trend for BioHarvest Sciences Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it will perform in line with the market [6]

Financial Data and Key Metrics Changes - Total revenues increased 39% year-over-year to $9.1 million in Q3 2025, compared to $6.5 million in Q3 2024 [3][13] - Gross profit increased 50% to $5.6 million, representing 61% of total revenue, up from 57% in the same year-ago quarter [13][14] - Adjusted EBITDA loss narrowed to $0.4 million in Q3 2025 from a loss of $1.7 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Product revenue grew 30% to $8.4 million, while CDMO revenue surged 722% to $0.7 million [13][14] - Core capsules accounted for 88% of product revenues, with new products contributing approximately 30% of growth [4][5] Market Data and Key Metrics Changes - The US VINIA active user base exceeded 75,000 customers, contributing to revenue growth [3] - The launch of VINIA BloodFlow Hydration targets the $17 billion US electrolyte hydration market [9] Company Strategy and Development Direction - The company operates two business verticals: direct-to-consumer products and CDMO services, aiming to drive revenue from both branded products and B2B partnerships [4] - The recent capital raise of $19.9 million will fund the next growth phase, including tripling manufacturing capacity and expanding CDMO services [11][12] - The company aims to achieve adjusted EBITDA break-even by early 2026, with a focus on revenue growth and margin improvement [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA soon, emphasizing the importance of scaling operations and maintaining cost discipline [15][17] - The company is focused on executing the rollout of new products and expanding its Health Pros Affiliate Program to enhance customer acquisition [16][17] Other Important Information - The company secured a new CDMO partnership with SaffronTech to develop saffron-derived compounds, retaining a 25% ownership of the resulting product [5][6] - Gross profit margins improved due to increased manufacturing scale and improved yields [14] Q&A Session Summary Question: Expectations for the ramp-up of the new hydration product - Management indicated a staged launch with initial positive responses and expects a quarter-on-quarter ramp-up in sales, particularly after the broader launch on December 3 [19][22] Question: Update on CDMO opportunities and SaffronTech agreement - Management detailed the collaboration with SaffronTech, emphasizing a fast-tracked development process and the potential for a quick market entry [24][26] Question: Progress on existing CDMO contracts - Management provided updates on ongoing CDMO agreements, highlighting progress in the cosmetic fragrance space and the Tate & Lyle agreement [32][33] Question: Long-term outlook for CDMO business - Management projected that by 2027-2028, approximately 75% of revenue could come from the CDMO business, with margins significantly higher than the product business [47][49] Question: Early success with the HealthPros program - Management reported strong early engagement and conversion rates from HealthPros, with plans to onboard 300 professionals by year-end [41][43]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive is committed to technology adoption, utilizing various tools to enhance workflows and content production [4][5] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - BioHarvest Sciences Inc. will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY [2] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during the event [3] - The company is experiencing strong momentum in both its consumer and CDMO divisions, with robust performance in its core VINIA® capsule business and new product lines [4] Company Performance - BioHarvest's VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution are expanding the company's market reach [4] - The CDMO platform has achieved significant milestones, including advancements in plant-based exosome production and a new contract for developing a saffron compound [4] - The company successfully closed a $19.9 million equity offering, which is expected to support its goal of achieving adjusted EBITDA breakeven in the near term [4] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - BioHarvest Sciences Inc. has successfully closed a public offering of common stock, raising $19.9 million to support its growth initiatives and operational needs [2][4]. Group 1: Offering Details - The public offering consisted of 2,846,854 shares at a price of $7.00 per share, including 361,854 shares from the underwriters' option to purchase additional shares [2][3]. - The gross proceeds from the offering amounted to $19.9 million before deducting underwriting discounts and other expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for immediate funding of manufacturing expansion, research and development, marketing, debt reduction or refinancing, capital expenditures, and general corporate purposes, including working capital [3][4]. Group 3: Company Background - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to cultivate the actual plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Points - BioHarvest Sciences Inc. has announced a public offering of 2,485,000 shares of common stock priced at $7.00 per share, aiming for gross proceeds of approximately $17.4 million [1][2] - The company has granted underwriters a 30-day option to purchase an additional 372,750 shares at the public offering price [1] - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on September 8, 2025 [3] Use of Proceeds - The net proceeds from the offering are expected to be utilized for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes, including funding working capital [2] Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to grow plant-based compounds without the need for the underlying plants [5] - The company operates in two major business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5]

Core Viewpoint - BioHarvest Sciences Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. - Craig-Hallum is the sole managing underwriter for the offering [2]. - A preliminary prospectus supplement will be filed with the SEC, detailing the terms of the proposed offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for various purposes, including research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to grow the plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Core Viewpoint - BioHarvest Sciences Inc. will release its third quarter financial results for 2025 on November 13, 2025, after market close, and will host an investor conference call to discuss these results and provide a corporate update [1][2]. Group 1: Earnings Call Details - The earnings call is scheduled for November 13, 2025, at 4:30 p.m. Eastern Time [2]. - Participants can join the call using the U.S./Canada dial-in number 1-877-300-8521 or the international dial-in number 1-412-317-6026, with a conference ID of 6486821 [2]. - A telephone playback of the call will be available until November 27, 2025, and a webcast replay will also be accessible [3]. Group 2: Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to cultivate the actual plants [4]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) for complex molecules and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4].